181 related articles for article (PubMed ID: 19729688)
1. Role of matrix metalloproteinases in coronary artery disease.
Shah VK; Shalia KK; Mashru MR; Soneji SL; Abraham A; Kudalkar KV; Vasvani JB; Sanghavi ST
Indian Heart J; 2009; 61(1):44-50. PubMed ID: 19729688
[TBL] [Abstract][Full Text] [Related]
2. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
3. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
[TBL] [Abstract][Full Text] [Related]
4. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
6. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
[TBL] [Abstract][Full Text] [Related]
7. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
9. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
[TBL] [Abstract][Full Text] [Related]
10. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome.
Liu DM; Yan JC; Wang CP; Chen GH; Ding S; Liu PJ; Du RZ
Clin Chim Acta; 2008 Nov; 397(1-2):22-6. PubMed ID: 18674525
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
[TBL] [Abstract][Full Text] [Related]
12. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome.
Yan JC; Wu ZG; Kong XT; Zong RQ; Zhan LZ
Acta Pharmacol Sin; 2004 Feb; 25(2):251-6. PubMed ID: 14769218
[TBL] [Abstract][Full Text] [Related]
13. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
[TBL] [Abstract][Full Text] [Related]
15. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction.
Suzuki H; Kusuyama T; Sato R; Yokota Y; Tsunoda F; Sato T; Shoji M; Iso Y; Koba S; Katagiri T
Eur J Clin Invest; 2008 Mar; 38(3):166-73. PubMed ID: 18257779
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease--KOZANI STUDY.
Kadoglou NP; Lampropoulos S; Kapelouzou A; Gkontopoulos A; Theofilogiannakos EK; Fotiadis G; Kottas G
Transl Res; 2010 May; 155(5):238-46. PubMed ID: 20403579
[TBL] [Abstract][Full Text] [Related]
17. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
18. Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction.
Papadopoulos DP; Economou EV; Makris TK; Kapetanios KJ; Moyssakis I; Votteas VE; Toutouzas PK
Drugs Exp Clin Res; 2004; 30(2):55-65. PubMed ID: 15272643
[TBL] [Abstract][Full Text] [Related]
19. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
20. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression.
Gurbel PA; Kreutz RP; Bliden KP; DiChiara J; Tantry US
Am Heart J; 2008 Jan; 155(1):56-61. PubMed ID: 18082490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
